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ABSTRACT
Objective: To provide an overview of risk factors, presentation and management of 
human cryptosporidium infection. 
Data sources: Literature review was obtained through PubMed search. 
Data selection: Published articles on the taxonomy of Cryptosporidium and the 
epidemiology, clinical presentation and management of cryptosporidiosis were 
reviewed. 
Data extraction and synthesis: Abstracts and complete articles relevant to the objective 
were selected, read and analysed to extract information for this article.
Conclusions: Human cryptosporidiosis is a severe diarrhoeal disease in malnourished 
children and immuno-compromised adults in whom it confers poor prognosis. 
Management is mainly supportive as drug therapy remains elusive. Fortunately the 
prevalence in AIDS patients is declining due to the widespread use of combination 
antiretroviral therapy (cART). 
water contaminated by mammal faeces. In developing 
countries, most people are infected during childhood 
(6). Serologic and stool studies have documented 
high rates of infection in Latin America, Africa, the 
Middle East, and South Asia. Overall, about 13% of 
stool studies submitted for parasitological studies in 
developing countries reveal Cryptosporidium oocysts, 
however, in patients with AIDS and diarrhoea the 
rate of cryptosporidiosis has been found to be as high 
as 72% (10, 11). Like other opportunistic infections, 
the prevalence of cryptosporidiosis in AIDS patients 
has dropped dramatically due to wide spread use 
of ARVs. Humans acquire Cryptosporidium infection 
through several transmission routes with person to 
person transmission playing a major role among the 
elderly and paediatric populations in nursing homes 
and day care centres respectively (12). In rural areas 
infection via contact with domestic animals has been 
reported (13) and in urban centres in the developed 
countries contaminated food and/or water have been 
identified as sources of outbreaks (14). 
 Cryptosporidiosis is promoted in an environment 
with large numbers of infectious oocysts and 
susceptible hosts. Oocysts in such an environment 
have many possible sources ranging from domestic 
livestock such as cattle, sheep and horses (15) to pets 
such as cats and dogs (16). Wild animals also act as 
reservoirs as they may contaminate water or food in 
environments shared by their domestic counterparts 
(17). Infected humans some of whom may be 
INTRODUCTION
Human cryptosporidiosis is caused by infection 
with the Apicomplexa protozoan of the genus 
Cryptosporidium. Human illness was formerly thought 
to be caused by a single species, but molecular studies 
have demonstrated that several different species 
cause human cryptosporidiosis. Among the more 
common species are Cryptosporidium hominis, for which 
humans are the only natural host and Cryptosporidium 
parvum, which infects bovines as well as humans(1). 
However, C. canis, C. felis, C. meleagridis and C. muris 
have also been found in patients with HIV infection, 
thus having the potential to cause human disease (2). 
Lately, other genotypes including cervine genotype 
have also been implicated in human disease (3-5). 
Cryptosporidiosis is one of the most common causes 
of diarrhoea in humans with peak incidence occurring 
in children under two years (6). The pathogenicity of 
Cryptosporidium varies with the species of parasites 
involved and the type, age, and immune status of the 
host.  In immuno-compromised individuals due to 
HIV infection, post transplant therapy or malnutrition 
(children), the infection is frequently chronic and can 
eventually lead to death (1, 7). 
Epidemiology: Infection by Cryptosporidium has been 
reported around the world in both immunocompetent 
and immunocompromised individuals (4,8,9). 
Transmission is usually faeco-oral, often through 
90 EAST AFRICAN MEDICAL JOURNAL February 2009 
asymptomatic also shed oocysts and contribute to 
the cycle. Most human outbreaks of water borne 
cryptosporidiosis are caused by the human genotype 
of C. parvum (18), however, C. hominis has also been 
reported in some instances (19) suggesting that 
human waste is an important source of oocyst for 
the outbreaks. 
 Cryptosporidiosis is one of the most common 
causes of diarrhoea in humans with peak incidence 
occurring in children under two years (6) and has 
been reported to be a major cause of morbidity 
and mortality throughout the world with infection 
outbreaks usually being linked to contaminated water 
(20). Young children are particularly susceptible 
especially in the malnourished in whom poor outcome 
has been confirmed in a control study in Ghana (7). 
Cryptosporidiosis and HIV infection: Gastrointestinal 
(GI) diseases are the most common presentation of 
acquired immunodeficiency syndrome (AIDS) in the 
third world with diarrhoea and weight loss being 
common. 
 Aetiology of chronic diarrhoea in Human 
Immunodeficiency Virus (HIV) infected / AIDS 
patients as identified by many workers comprises 
mainly Cryptosporidium spp, Microsporidium spp and 
Campylobacter. While comparing children with and 
without HIV infection both groups having persistent 
diarrhoea in Uganda’s Mulago Hospital, Tumwine 
et al (10)  showed that 73.6% of HIV positive had 
Cryptosporidium compared to only 5.9% of those 
without HIV. In Venezuela, Chacin-Bonilla et al 
(21) in a case control study involving 103 HIV 
infected outpatients found Cryptosporidium in 
13.6%. In Nairobi, Kenya (22) among 75 consecutive 
in-patients with HIV and diarrhoea, 52% had 
pathogens with Cryptosporidium spp being the most 
commont accounting for 17%. In a prospective study 
involving HIV infected and uninfected children with 
diarrhoea in Thailand (23) the most common parasites 
were Cryptosporidium and Microsporidium. Thus 
cryptosporidiosis is one of the major causes of chronic 
diarrhoea especially in HIV infected individuals. 
 Published studies describing the prevalence and 
epidemiology of cryptosporidiosis in patients with 
HIV infection present markedly different estimates 
ranging from 0 to 100% as reviewed by Hunter and 
Nichols (24). However, these studies are unanimous 
in finding that the risk of infection increases with 
decreasing immunity as measured by CD4+ T 
lymphocyte cell count (25). In addition, various social 
and behavioural factors such as sexual behaviour, 
gender and rearing pets and livestock have also been 
reported to increase risk of infection. In a multi- centre 
European study the risk of cryptosporidiosis was 
significantly lower for intra-venous drug users than 
homosexual men (RR 0.34; 95%CI 0.22 - 0.54) and for 
women than men (RR 0.43; 95%CI 0.21 - 0.87) (26). 
A large US study (27) has shown that prevalence of 
cryptosporidiosis was higher in persons who acquired 
HIV through sexual contact (3.9% p<0.01) than those 
with other HIV exposure categories (2.6% p<0.0l). 
Keeping pets also poses a risk as reported by Glaser, 
et al (28). 
 Blanshard  et al (29) described various 
presentations of cryptosporidiosis in HIV positive 
patients in London; 5% of all patients and 21% of 
all AIDS patients had cryptosporidiosis.  Transient 
infection was noted in 28.7% chronic disease in 
59.7%, asymptomatic disease in 3.9% and fulminant 
disease in 7.8%. In later studies, US workers found 
chronic diarrhoea in 36%, cholera like (fulminant) 
disease in 33% and transient diarrhoea in 15% with 
shorter survival among the infected (30). Only 
those with CD4+ T-lymphocytes of less than 50 
cells/ml get fulminant disease (31). Outcome of 
Cryptosporidiosis in HIV infected patients is related 
to CD4+ T -lymphocyte count and haematocrit level 
at the time of diagnosis. Colford, et al (32) have shown 
that the median survival of those with CD4 count 
of >53/ml and haematocrit of >37% was 1,119 days 
compared to 204 days for those with less. In Kenya, 
Mwachari et al (22) have demonstrated that among 
HIV positive patients with diarrhoea, the presence 
of Cryptosporidium was the single most significant 
predictor of death when compared with other enteric 
infections. 
Pathophysiology: Cryptosporidium oocysts are highly 
infectious, requiring only 101-103 oocysts to cause 
human disease (11). Upon oocyte excystation, four 
sporozoites are released which adhere to the surface 
of intestinal mucosa (33) with the aid of sporozoite-
specific lectin adherence factor before gaining 
residence in the intracellular space but outside the 
cytoplasm (11). It is suspected that the parasite 
stimulates the mucosal cells to release cytokines that 
activate resident phagocytes (33). Host response to 
the infection includes a combination of increased 
intestinal permeability, chloride secretion and mal-
absorption resulting in diarrhoea (6, 33). In patients 
with AIDS or any form of immune deficiency, the 
biliary tract may be involved. 
Clinical presentation: After an incubation period of 5-10 
days (range 2-28 days), the patient develops watery 
diarrhoea, which may be associated with abdominal 
cramps and a low-grade fever lasting for about 5-10 
days but may persist for 2-4 weeks. Patients with AIDS 
and very low CD4 cell counts may develop profuse, 
cholera-like diarrhoea, which can be complicated 
by volume depletion and malabsorption. Biliary 
tract involvement which may include acalculous 
cholecystitis, sclerosing cholangitis, papillary 
stenosis, or pancreatitis seen in AIDS patients with 
very low CD4 cell counts and children with X-linked 
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immunodeficiency with hyper-IgM is associated with 
right upper quadrant pain, nausea, and vomiting. 
Some patients remain asymptomatic. 
 Physical findings are non-specific with low 
grade fever and temperature higher than 39°C is not 
characteristic of cryptosporidiosis. Signs of volume 
depletion or wasting from malabsorption may be 
found. 
Investigations: Most tests to detect Cryptosporidium 
involve direct microscopic detection of the parasite in 
tissues or faecal specimen. Modified acid-fast staining 
of stool (red-stained round oocysts against a blue-
green background) is the commonly used laboratory 
test due to its low cost and simple methodology (34). 
However, the staining methods have shown low 
sensitivity ranging from 33.3% to 41% with stool 
specimen (35). The relatively low sensitivity with 
faeces can be improved tremendously by examination 
of prepared slides under UV light with a rhodamine 
(540-560 nm) filter (36). Antibody based tests are also 
available but more expensive than staining techniques 
with similar sensitivity and specificity (37). 
 Antigen-detection assays are more sensitive 
(35, 38) and include immunofluorescent assays, 
enzyme-linked immunosorbent assay (ELISA), 
immunochromatographic tests as well as Polymerase 
Chain Reaction (PCR) (39) but are not readily available 
for clinical use.  Stool culture is necessary to rule 
out the presence of other bacterial pathogens. Other 
tests like createnine, urea, serum proteins, full blood 
count, CD4 e.t.c. may be used to gauge severity 
of the condition and immune status. Imaging and 
endoscopic studies like ERCP are needed when 
extraintestinal complications are suspected. 
 Histology of the small intestine shows the 
parasite projecting from the brush border of the 
mucosal surface but this examination is not required 
to confirm the diagnosis of cryptosporidiosis. The 
parasites may also be identified in bile or biliary tract 
biopsies. 
Treatment: There is lack of effective chemotherapeutic 
agents or vaccines against Cryptosporidium (3). 
Intracellular location and innate resistance to 
many agents have rendered the treatment of 
Cryptosporidiosis difficult and frustrating (3). Most 
agents that have been investigated as treatments 
for cryptosporidiosis received mixed success (40). 
Paromomycin an amino glycoside antibiotic with 
antibacterial spectrum similar to that of neomycin 
has been used as an oral, first-line agent in 
cryptosporidiosis with mixed results. 
 White et al. (41) reported a significant reduction 
in stool frequency and oocyst excretion during 
treatment. In contrast, Hewitt et al. (42) compared 
paromomycin with placebo in 35 cryptosporidiosis 
cases with CD4 cells of less than 150 cells/mm3 and 
found no difference between the two arms in terms 
of diarrhoea, weight or oocyst excretion. Interestingly, 
paromomycin, alone or in combination with 
Azithromycin has been accepted for symptom control. 
Nevertheless, the combination is too expensive. 
 Oral spiramycin, a macrolide antibiotic, showed 
promise initially but efficacy in HIV-positive patients 
has never been demonstrated (43). Azithromycin, 
another macrolide, has shown mixed results as 
reported by various workers. Kadappu et al (44) 
reported good clinical response after a seven day 
course in 13 HIV -positive individuals, but oocyst 
shedding persisted in majority even after two weeks. 
Allam et al (45) and Trad et al. (46) have reported 
success with azithromycin with up to 99% reduction 
in oocysts after three weeks of treatment, whereas, 
others have failed to record any significant response 
to the drug (47, 48). Clarithromycin of the same group, 
has shown some promise as a prophylactic agent 
(49) however, in one retrospective analysis involving 
2,288 patients clarithromycin did not decrease risk 
of cryptosporidiosis (50). Sprinz et al. (51) found that 
50% of 24 patients had complete symptom remission 
and 29% partial response when given four weeks of 
roxithromycin therapy. 
 So far the most promising  agent in recent years 
is nitazoxanide (2-acetyloxy-N-(5-nitro-2 thiazolyl) 
benzamide) a synthetic antiparasitic agent for 
oral administration that is rapidly hydrolysed to 
its active metabolite tizoxanide. Amadi et al. (52) 
in random placebo controlled study involving 50 
HIV -positive and 50 HIV -negative children with 
cryptosporidiosis confirmed significant efficacy 
and reduced mortality in nitazoxanide arm. Using 
higher doses though, Rossignol et al. (53) confirmed 
nitazoxanide to be significantly better than placebo. 
More recently nitazoxanide, improved clinical 
outcomes in 56% of HIV negative malnourished 
Zambian children with quick parasite clearance 
rate (54). Other agents with activity against 
Cryptosporidium include Ionophores (lasalocid and 
maduramycin). Passive antibody immunotherapy 
with bovine colostrum from cows hyperimmunised 
with Cryptosporidial cysts has been tried with 
limited success (55). 
 Symptomatic therapy includes replacement of 
fluids, nutrition and treatment of diarrhoea. Anti-
diarrhoeal agents; Loperamide, diphenoxylate-
atropine, somatostatin analogues (octreotide) or 
opiates are used in combination with antiparasitic 
agents. Attention to nutritional aspects of patient 
care is crucial because malnutrition can cause death. 
Lactose intolerance is common in cryptosporidiosis, 
and lactose-containing foods should be avoided. 
Patients with acalculous cholecystitis should 
generally be treated with cholecystectomy. 
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Prevention: Drinking water, especially for AIDS 
patients should be purified by using 1-micron water 
filters in countries with high risk of transmission (56). 
Avoidance of newborn animals including domestic 
ones helps in preventing transmission specifically 
new pets for patients with AIDS should be older than 
six months and should not have diarrhoea. Hand 
washing should also be practiced by those in health 
care and child care to avoid faeco-oral transmission 
Prognosis: Children with persistent diarrhoea 
develop worsening malnutrition, which may result in 
cognitive and fitness problems that persist for years 
(33). Chronic cryptosporidiosis may be complicated 
by biliary tract disease, malabsorption, and death 
in AIDS patients and malnourished children. 
Prolonged diarrhoea (> 1 mo) and biliary disease 
indicate a poor prognosis in patients with AIDS. In 
immunocompetent individuals Cryptosporidium 
causes self limiting watery or mucoid diarrhoea with 
abdominal pain (24). 
CONCLUSION
Human cryptosporidiosis is a severe diarrhoeal disease 
in malnourished children and immunocompromised 
adults in whom it confers poor prognosis. 
Management is mainly supportive as drug therapy 
remains elusive. Fortunately the prevalence in AIDS 
patients is declining due to the widespread use of 
combination antiretroviral therapy (cART). 
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